Wirkung von Apomorphin auf nicht motorische Symptome bei Morbus Parkinson

Zusammenfassung

Nicht motorische Symptome können bereits vor den motorischen Symptomen einer Parkinsonerkrankung auftreten. Neben Wirkungsfluktuationen und Dyskinesien stellen nicht motorische Symptome ein Hauptproblem in der Behandlung der fortgeschrittenen Parkinsonerkrankung dar. Sie sind von wesentlicher Bedeutung für die Lebensqualität. Es gibt Hinweise darauf, dass eine kontinuierliche dopaminerge Stimulation Depression, Schlaf und autonome Störungen verbessern kann. Medikamentenpumpen mit Apomorphin subkutan oder Duodopa (L-Dopa / Carbidopagel) intraduodenal haben sich zur Behandlung von motorischen Wirkungsfluktuationen und Dyskinesien etabliert. Im Bereich der nicht motorischen Symptome liegen bisher nur wenige Studien mit kleinen Fallzahlen vor.

Abstract

In Parkinson's disease non-motor symptoms can appear even before the motor symptoms. Additionally to motor fluctuations and dyskinesias, the non-motor symptoms constitute one of the main problems when treating Parkinson's disease. They are also of high relevance for the quality of life. There are indications that a continuous dopaminergic stimulation can improve symptoms such as depression, sleep as well as autonomic disturbances. Treatment with apomorphine infusion subcutaneously or Duodopa (L-dopa / carbidopa) intraduodenally with portable pump systems are well-established regarding management of motor fluctuations and dyskinesias. Regarding effects on non-motor symptoms there are so far only a few studies with limited number of cases available.

Schlüsselwörter

Parkinson - Pumpe - Apomorphin - Infusion - Non-motor

Keywords

Parkinson - pump - apomorphine - infusion - non-motor

Literatur

• 1 Chaudhuri K R, Healy D, Schapira A HV. The non motor symptoms of Parkinson's disease. Diagnosis and management.  Lancet Neurol. 2006;  5 235-245
• 2 Naidu Y, Chaudhuri K R. Early Parkinson's disease and non motor issues.  J Neurol. 2008;  255 33-38
• 3 Tolosa E et al. Diagnosis and the premotor phase of Parkinson disease.  Neurology. 2009;  72 (S 02) S12-S20
• 4 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson's disease and Related Disorders. Park Related Disorders P0II: 161.. Dresden; October/2008
• 5 Chaudhuri K R, Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease.  Eur J Neurol. 2008;  15 2-7
• 6 Chaudhuri K R, Martinez-Martin P, Schapira A HV et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study.  Mov Disord. 2006;  21 916-923
• 7 Politis M, Piccini P, Pavese N et al. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C raclopride study.  Exp Neurol. 2008;  214 112-116
• 8 Storch A, Ebersbach G, Fuchs G et al. Depression in Parkinson's disease. Part 1: Epidemiology, signs and symptoms, pathophysiology and diagnosis.  Fortschr Neurol Psychiatr. 2008;  76 715-724
• 9 Remy P, Doder M, Lees A et al. Depression in Parkinson's disease. Loss of dopamine and noradrenaline innervations in the limbic system.  Brain. 2005;  128 1314-1322
• 10 Corrigan M H, Denahan A Q, Wright C E et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.  Depress Anxiety. 2000;  11 58-65
• 11 Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.  Eur J Neurol. 2003;  10 399-406
• 12 Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel group randomized study.  J Neurol. 2006;  253 601-607
• 13 Reichmann H, Brecht M H, Koster J et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.  CNS Drugs. 2003;  17 965-973
• 14 Pahwa R, Stacy M A, Factor S A EASE-PD adjunct study investigators et al, on behalf of the . Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.  Neurology. 2007;  68 1108-1115
• 15 Naidu Y, Logishetty K, Martin A et al. Efficacy of apomorphine infusion on mood and depression aspects of non-motor symptoms in advanced Parkinson's disease.  Park Rel Disord. 2009;  15 (S 02) S130 (P2.149)
• 16 Kulisevsky J, Pascual-Sedano B, Barbanoj M et al. Acute effects of immediate and controlled release levodopa on mood in Parkinson's disease: a double blind study.  Mov Disord. 2006;  22 62-67
• 17 Witt K, Daniels C, Reiff J et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study.  Lancet Neurol. 2008;  7 605-614
• 18 Hagell P, Odin P, Shing M. Apomorphin bei Morbus Parkinson.. Bremen: Uni-Med Verlag; 2005
• 19 Colzi A, Turner K, Lees A J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1998;  64 573-576
• 20 Richard I H, Schiffer R B, Kurlan R. Anxiety and Parkinson's disease.  J Neuropsychiatry Clin Neurosci. 1996;  8 383-392
• 21 Pluck G C, Brown R G. Apathy in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 2002;  73 636-642
• 22 Czernecki V, Schupbach M, Yaici S et al. Apathy following subthalamic stimulation in Parkinson's disease: a dopamine responsive syndrome.  Mov Disord. 2008;  23 964-969
• 23 Marin R S, Fogel B S, Hawkin J et al. Apathy: a treatable syndrome.  J Neuropsychiatry Clin Neurosci. 1995;  7 23-30
• 24 Goetz C G, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.  Ann Neurol. 2008;  64 (S 02) S81-92
• 25 Cools R, Stefanova E, Barker R et al. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET.  Brain. 2002;  125 584-594
• 26 Mattay V, Tessitore A, Callicott J et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease.  Ann Neurol. 2002;  51 156-164
• 27 O'Sullivan S S, Evans A H, Lees A J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.  CNS Drugs. 2009;  23 157-170
• 28 Lees A J, Blackburn N A, Campbell V L. The nighttime problems of Parkinson's disease.  Clin Neuropharmacol. 1988;  11 512-519
• 29 Askenazy J J. Sleep disturbances in Parkinsonism.  J Neural Transm. 2003;  110 125-150
• 30 Dhawan V, Healy D G, Pal S et al. Sleep-related problems of Parkinson's disease.  Age Ageing. 2006;  35 220-228
• 31 Stocchi F, Vacca L, Valente M et al. Sleep disorders in Parkinson's disease.  Adv Neurol. 2001;  86 289-293
• 32 Diederich N, Comella C. Sleep disturbances in Parkinson's disease.. In: Chokroverty S, Hening W A, Walters A, eds Sleep and Movement Disorders.. Philadelphia: Butterworth, Heinemann; 2003: 478-488
• 33 Trenkwalder C, Boesch S, Ceballos-Baumann A et al. Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement.  Nervenarzt. 2008;  79 475-479
• 34 Garcia Ruiz P J. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.  Mov Disord. 2006;  21 727-728
• 35 Ng K Y, Chase T N, Colburn R W et al. Dopamine stimulation induced release from central neurons.  Science. 1971;  1172 487-489
• 36 Rye D B, Jankovic J. Emerging views of dopamine in modulating sleep / wake state from an unlikely source: PD.  Neurology. 2002;  58 341-346
• 37 Uchiyama T, Sakakibara R, Hattori T et al. Short-term eff ect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon.  Mov Disord. 2003;  18 573-578
• 38 Christmas T, Kempster P, Chapple C et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction.  Lancet. 1988;  2 1451-1453
• 39 Mitra T, Naidu Y, Martinez-Martin P et al. The non declaration of non motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson's disease and Related Disorders. Park Related Disorders P0II: 161.. Dresden; October/2008
• 40 O'Sullivan J D, Hughes A J. Apomorphine induced penile erections in Parkinson's disease.  Mov Disord. 1998;  13 536-539
• 41 Dula E, Bukofzer S, Perdok R et al. Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.  Eur Urol. 2001;  39 558-564
• 42 Klos K J, Bower J H, Josephs K A et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.  Park Relat Disord. 2005;  11 381-386
• 43 Edwards L L, Quigley E MM, Harned R K et al. Defecatory function in Parkinson's disease: response to apomorphine.  Ann Neurol. 1992;  33 490-493
• 44 Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life.  Mov Disord. 2009;  24 1468-1474
• 45 Brefel-Courbon C, Payoux P, Thalamas C et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.  Mov Disord. 2005;  20 1557-1563
• 46 Witjas T, Kaphan E, Azulay J P et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling.  Neurology. 2002;  59 408-413
• 47 Ray Chaudhuri K, Abbott R J, Millac P AH. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.  J Neurol Neurosurg Psychiatry. 1990;  54 372-373
• 48 Ellis C M et al. Use of apomorphine therapy in parkinsonian patients with neuropsychiatric complications to oral therapy.  Parkinsonism and Related Disorders. 1997;  3 103-107
• 49 van Laar T, Postma A G, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.  Park Relat Disord. 2010;  16 71-72
• 50 Martinez-Martin P, Todorova A, Henriksen T et al. The motor and non motor efficacy of subcutaneous apomrophine infusion in chronic advanced PD compared to Parkinson's patients on conventional therapy. A „real life” study.  Mov Disord 2010. Abstract In Press. To be Presented to Movement Disorders Congress. Buenos Aires; June 2010